These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2006-004886-33 A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND IMMUNOMODULATORY THERAPY FOR THE MANAGEMENT OF SEPSIS not-yet-due
Completed, but no date Terminated 2007-004289-42 90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) bad-data
Completed, but no date 2008-004807-67 AN OPEN-LABEL, NON-RANDOMIZED PHASE IV CLINICAL TRIAL OF THE EFFICACY OF INTRAVENOUSLY ADMINISTERED 1000MG PARACETAMOL AS ANTIPYRETIC AND ANALGESIC MEDICATION bad-data
Not reported 2010-021413-23 Optimizing Dosing of Colistin for Infections Resistant to all Other Antibiotics 2014-08-01 due-trials
Not reported 2011-005145-12 A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF ANAKINRA IN PATIENTS WITH HIDRADENITIS SUPPURATIVA (PROTOCOL: HIDRA03) 2014-08-01 due-trials
Not reported 2011-005333-39 The effects of acute sildenafil administration on inflammatory markers in patients with vasculogenic erectile dysfunction. 2014-01-17 due-trials
Not reported 2012-000933-37 Phase II trial of ofatumumab combined with ESHAP as salvage therapy before autologous stem cell transplantation, for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) previous... 2016-01-11 due-trials
Ongoing 2012-004819-31 Multicenter open-label RCT to compare colistin alone vs. colistin plus meropenem not-yet-due
Ongoing 2012-004998-53 A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia. not-yet-due
Ongoing 2015-005630-21 A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr with Acetylsalicylic Acid versus CLopidogrel with Acety... not-yet-due
Ongoing 2016-002586-64 A randomized, pharmacodynamic study of cangrelor administration in STEMI patients loaded with ticagrelor not-yet-due
Ongoing 2016-004959-80 A randomized, pharmacodynamic comparison of ticagrelor 60mg bid vs prasugrel 5mg in patients with prior myocardial infarction not-yet-due